Wearable cardioverter-defibrillator use in clinical settings in Poland: Nationwide observational cohort study
Maciej Sterliński(Institute of Cardiology), Jerzy Krzysztof Wranicz(Medical University of Lodz), Sławomir Dobrzycki(Medical University of Silesia), Marcin Grabowski, Oskar Kowalski(Silesian Center for Heart Disease), Ludmiła Daniłowicz‐Szymanowicz(Gdańsk Medical University), Andrzej Przybylski(University of Rzeszów), Przemysław Mitkowski(Poznan University of Medical Sciences), Karolina Kryczka(Cardinal Stefan Wyszynski University in Warsaw), Bartosz Olajossy(1 Military Clinical Hospital with Outpatient Clinic), Łukasz Szumowski(Institute of Cardiology), Maciej Kempa(Gdańsk Medical University), Piotr Wieniawski(Medical University of Warsaw), Adrian Włodarczak(Centrum Badań Jakości), Marek Gierlotka(University of Opole), Michał M. Farkowski(Institute of Cardiology), Agnieszka Pawlak(Ministry of Interior), Jarosław Kaźmierczak, Andrzej Bissinger(Nicolaus Copernicus University), Robert Gil(Ministry of Interior and Administration), Paweł Ptaszyński(Medical University of Lodz), Tomasz Chyży(John Paul II Hospital), Adam Sokal(Silesian Center for Heart Disease), Mateusz Tajstra(Silesian Center for Heart Disease), Jakub Baran(Medical University of Warsaw), Joanna Płonka(University of Opole), Bartłomiej Wróbel(Corona (Poland)), Zofia Dzielińska(Cardinal Stefan Wyszynski University in Warsaw), Ewa Świerżyńska-Wodarska(Cardinal Stefan Wyszynski University in Warsaw), Adam Wojtaszczyk(Medical University of Lodz)
Cited by 5
Related Papers
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889